The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy.
 
Lukas Delasos
Consulting or Advisory Role - MJH Life Sciences; Primum
 
Bryan Berube
No Relationships to Disclose
 
Maedeh Zokaei Nikoo
No Relationships to Disclose
 
Wei Wei
No Relationships to Disclose
 
Marc A. Shapiro
Consulting or Advisory Role - Anthem
 
Khaled Aref Hassan
No Relationships to Disclose
 
James Stevenson
Consulting or Advisory Role - Arcus Biosciences
Research Funding - Amgen (Inst); Black Diamond Therapeutics (Inst); Merck Sharp & Dohme (Inst); PrECOG (Inst)
 
Alex A Adjei
Consulting or Advisory Role - EMD Serono; Janssen; Mirati Therapeutics; Swiss Rockets; Zai Lab
Research Funding - Bayer Schering Pharma (Inst); I-Mab (Inst); Jacobio (Inst); Kura Oncology (Inst); Merck KGaA (Inst); Tesaro (Inst); Zai Lab (Inst)
(OPTIONAL) Uncompensated Relationships - Merck KGaA; Swiss Rockets; Zai Lab
 
Nathan A. Pennell
Consulting or Advisory Role - Anheart Therapeutics; Bayer; Genentech; Iovance Biotherapeutics; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Picture Health; ResistanceBio; Sanofi/Regeneron; Summit Therapeutics; Takeda; Vial
Research Funding - Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Navire (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Summit pharmaceuticals (Inst)